BioSpace News Archive

Antibe Therapeutics Inc., a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health conditions, announced a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fortify Antibe’s intellectual property position for its current pipeline.

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor, also known as CCN2, for the treatment of idiopathic pulmonary fibrosis.

Dyne Therapeutics, Inc. (Nasdaq: DYN), is presenting today preclinical data from its facioscapulohumeral muscular dystrophy (FSHD) program during the 28th Annual FSHD Society International Research Congress.

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ™, a biosimilar candidate referencing Lucentis®1 (ranibizumab), also known as SB11.

M6P Therapeutics will participate in a fireside chat at the ROTH Virtual Private Company Forum.

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company’s annual general meeting.

Fact.MR: The optometry equipment market revenue surpassed US$3.8 Bn for 2018, according to Fact.MR. The optometry equipment overall market is expected to gain US$ 2 Billion worth incremental opportunity by 2029.

Sanofi announced today that its Q2 2021 Memorandum for modelling purposes is available on the “Investors” page of the company’s website

The CHMP adopted a positive opinion based on results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of Abecma in 128 patients with heavily pre-treated and highly refractory multiple myeloma.